Compare · GILD vs SCNI
GILD vs SCNI
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Scinai Immunotherapeutics Ltd. (SCNI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and SCNI operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $184.47B, about 127759.0x SCNI ($1.4M).
- Over the past year, GILD is up 29.7% and SCNI is down 81.6% - GILD leads by 111.3 points.
- GILD has been more active in the news (12 items in the past 4 weeks vs 4 for SCNI).
- GILD has more recent analyst coverage (25 ratings vs 0 for SCNI).
- Company
- Gilead Sciences Inc.
- Scinai Immunotherapeutics Ltd.
- Price
- $148.78+1.33%
- $2.82-3.75%
- Market cap
- $184.47B
- $1.4M
- 1M return
- +13.98%
- +22.61%
- 1Y return
- +29.69%
- -81.57%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2015
- News (4w)
- 12
- 4
- Recent ratings
- 25
- 0
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest GILD
- European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
- Director Bluestone Jeffrey exercised 5,000 shares at a strike of $67.04 and sold $725,078 worth of shares (5,000 units at $145.02) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $415,080 worth of shares (3,000 units at $138.36) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 165,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna exercised 25,000 shares at a strike of $67.07 and sold $3,853,908 worth of shares (28,000 units at $137.64) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 118,234 units (SEC Form 4)
- EVP Gen Counsel, Legal & Comp Cain Wettan Keeley M covered exercise/tax liability with 2,908 shares and converted options into 6,002 shares, increasing direct ownership by 58% to 8,454 units (SEC Form 4)
- SEC Form S-3ASR filed by Gilead Sciences Inc.
- SEC Form 10-Q filed by Gilead Sciences Inc.
- CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results
- Chairman & CEO O'Day Daniel Patrick sold $1,954,694 worth of shares (15,000 units at $130.31) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 592,133 units (SEC Form 4)
- Gilead Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest SCNI
- SEC Form 6-K filed by Scinai Immunotherapeutics Ltd.
- Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum
- SEC Form 6-K filed by Scinai Immunotherapeutics Ltd.
- Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration
- Director Germain Mark was granted 120,000,000 units of Ordinary Shares (SEC Form 4)
- Chief Executive Officer Reichman Amir was granted 400,000,000 units of Ordinary Shares, increasing direct ownership by 128% to 711,637,600 units (SEC Form 4)
- SEC Form 6-K filed by Scinai Immunotherapeutics Ltd.
- SEC Form 6-K filed by Scinai Immunotherapeutics Ltd.
- Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives
- SEC Form 6-K filed by Scinai Immunotherapeutics Ltd.